Dossier
RevMed
Coverage of RevMed in the Nexus archive.
- STAT+: Will Makary’s FDA voucher program survive?
RevMed’s experimental pancreatic cancer drug, daraxonrasib, is available through an expanded access program but remains unapproved. The FDA’s voucher program led by Marty Makary may undergo changes.
- STAT+: A standing ovation for RevMed, and caution for Akeso
The article reports that RevMed received a standing ovation at the ASCO annual meeting, while Akeso faced caution. The event's plenary session concluded, but the conference continues with further sessions and a virtual recap.